Episode
LTR 146: Ganesh Sabat on Scaling MedTech Through Quality
- Podcast
- Let's Talk Risk! Podcast
- Published
- Mar 6, 2026
- Duration seconds
- 1535
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/ltr-146-ganesh-sabat-on-scaling-medtech-through-quality/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/ltr-146-ganesh-sabat-on-scaling-medtech-through-quality.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Summary “A company can become world class the day the quality team decides.” In this Let’s Talk Risk! conversation , host Naveen Agarwal engages with Ganesh Sabat, former former CEO of Sahajanand Medical Technologies (SMT) and now Founder & Managing Partner of MedArtha Capital about a simple but hard truth: global scale in MedTech is earned through quality execution, not marketing narratives. Ganesh walks through SMT’s transformation from an innovative startup into a globally recognized cardiovascular device company, then zooms out to India’s broader MedTech ambition. We unpack what’s missing (talent depth, shared learning, true design ownership), what’s emerging (incubation + device parks + incentives), and why quality leaders are the real “make-or-break” force behind India’s credibility on the world stage. Listen to the full 30-minute podcast or jump to a section of interest listed below. Chapters 00:00 Welcome and Introduction 02:09 SMT story: from “innovative startup” to global scale 04:54 The turning point: why Ganesh bet on quality as the growth lever 06:13 What investors demanded: proof, discipline, and scalable systems 08:39 India ecosystem reality: pharma-quality mindset vs device-grade rigor 11:22 “Quality as a system”: building defect prevention into process + design 15:21 Building the ecosystem: why shared learning + capability depth matter 18:58 Challenges and opportunities for MedTech startup 21:02 Achieving global success not through low-cost but high quality 24:25 Closing remarks If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter . Suggested links: LTR: What QA/RA Professionals Need to Know About MedTech in India . LTR: Navigating the Regulatory Landscape for SaMD in India . LTR: Atty Chakraborty on India’s Rising MedTe…